Date:28/07/2004 URL: http://www.thehindubusinessline.com/2004/07/28/stories/2004072801280400.htm

Back NPIL gets India rights for Dobutrex

Our Bureau

Mumbai , July 27

DRUG major Nicholas Piramal India Ltd (NPIL) has acquired the India rights for cardiac stimulant brand Dobutrex, from Eli Lily & Company of the US.

Though financial details of the acquisition remain undisclosed, NPIL officials told Business Line that Dobutrex had clocked sales of Rs 6.3 crore in 2003.

Dobutrex is an injectible cardiac stimulant used in situations such as heart attack and the drug has a 37 per cent market share in the local market, a company source said. The size of the cardiac stimulant market is estimated at Rs 17 crore, he added.

Meanwhile, an Eli Lilly official said that the company sold Dobutrex since it wanted to focus on its products in niche segments.